SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced the approval of a clinical trial application (CTA) by the Austrian regulatory authorities (BASG/AGES) for its development program SR-878. The upcoming clinical study aims to evaluate safety in healthy volunteers for the proprietary iRhom2-targeting monoclonal antibody SR-878 and provide initial evidence of clinical activity in a second part of the study. SciRhom expects to initiate the first dosing of study participants in the second half of 2024.
"We are entering a transformative period for SciRhom with our first-in-class antibody program SR-878 accelerating towards clinical studies. In parallel to transitioning into a clinical-stage drug development organization, SciRhom has established a comprehensive preclinical pharmacology and toxicology data package for the lead development program, a robust and efficient manufacturing process, and secured broad patent protection for iRhom2-targeting therapeutic strategies”, commented Dr. Jan Poth, Managing Director & CEO of SciRhom.
The target molecule iRhom2 acts as a crucial regulator of TACE/ADAM-17, a master switch for various disease-relevant signaling pathways. SR-878 was designed to simultaneously block several of these pathways, including TNF-alpha and IL-6R signaling. In preclinical models of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), SR-878 has demonstrated its ability to inhibit TACE activity potently and selectively in immune cells, facilitating tissue regeneration and immune re-balancing. In these preclinical studies, SR-878 as a monotherapy showed superior preclinical efficacy over individually used approved drugs for autoimmune disorders. Moreover, the toxicological assessment of SR-878 supported the expected favorable safety profile of the approach.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!